Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875894 | 0.95 | AOC3 (0.61) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4982439 | 0.90 | AOC3 (0.61) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5551577 | 0.90 | AOC3 (0.49) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4991737 | 0.89 | AOC3 (0.47) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4873929 | 0.88 | AOC3 (0.54) | AOC3 | |
| SCHEMBL4873656 | 0.88 | AOC3 (0.63) | AOC3MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL5545300 | 0.88 | AOC3 (0.62) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5551606 | 0.88 | AOC3 (0.64) | AOC3HTTMAPTNPSR1 | |
| SCHEMBL4988571 | 0.87 | AOC3 (0.45) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4984683 | 0.86 | AOC3 (0.44) | AOC3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885PIK3CD 4600/4885PIK3CA 4444/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885PIK3CD 4683/4885PIK3CA 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.